Chantal Parisien
About Chantal Parisien
Chantal Parisien is a Cellular Therapy Specialist at Bristol Myers Squibb, focusing on CAR T-cell therapy for multiple myeloma in Montreal, Quebec, Canada.
Current Role at Bristol Myers Squibb
Chantal Parisien currently serves as a Cellular Therapy Specialist - CAR T in Multiple Myeloma at Bristol Myers Squibb in Montreal, Quebec, Canada. In this role, she focuses on developing and implementing cellular therapy solutions, specifically CAR T-cell therapy, to treat multiple myeloma, a type of cancer that affects plasma cells.
Experience at Celgene and Roche
Before her current role, Chantal worked at Celgene as a Therapeutic Development Specialist in Hematology - Multiple Myeloma from 2014 to 2020 in Montreal, Canada Area. At Roche, she served in multiple positions, including Senior Therapeutic Specialist in Hematology - Lymphoma and CLL from 2005 to 2014, and Therapeutic Specialist in Oncology focusing on breast cancer, lung cancer, and lymphoma from 2003 to 2005.
Educational Background
Chantal Parisien holds an M.Sc. in Nutrition from the University of Montreal, where she studied from 1991 to 1993. This advanced scientific education has laid a strong foundation for her extensive career in the pharmaceutical and biotechnology industries.
Early Career and Bayer Experience
Chantal began her career at Bayer, where she worked from 1999 to 2003 in roles including GP Sales Representative and Specialist Representative focusing on cardiology and urology. Her diverse experience at Bayer provided her with a broad understanding of different therapeutic areas, which she later specialized in oncology and hematology roles.
Expertise in Multiple Therapeutic Areas
With over 20 years of experience, Chantal has amassed extensive expertise in therapeutic development for both solid tumors and hematologic malignancies. She has been involved in the development and commercialization of multiple oncology therapies, leveraging her deep knowledge in hematology, particularly multiple myeloma, lymphoma, and chronic lymphocytic leukemia (CLL).